Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
20-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
20-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
14 May 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/apellis-weak-syfovre-quarter-signals-uphill-climb-geographic-atrophy-med-mizuho
07 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/07/3075925/0/en/Apellis-Pharmaceuticals-Reports-First-Quarter-2025-Financial-Results.html
06 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/06/3074885/0/en/Apellis-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences.html
30 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/30/3071192/0/en/Apellis-Pharmaceuticals-to-Host-Conference-Call-on-May-7-2025-to-Discuss-First-Quarter-2025-Financial-Results.html
21 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/21/3064549/0/en/Apellis-Announces-Craig-Wheeler-to-Join-the-Board-of-Directors.html
01 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/01/3053146/0/en/Apellis-Announces-FDA-Acceptance-and-Priority-Review-of-the-Supplemental-New-Drug-Application-for-EMPAVELI-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html
ABOUT THIS PAGE